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Background
Understanding antibody generation and maintenance in
the context of HIV-1 infection and vaccination are key for
the development of an AIDS vaccine. Antigen-specific B-
cells can be enumerated with the ELISpot assay but B-cell
availability is generally limited. Therefore, a multiplex
detection system is needed to study multiple antibody
types. We report a multiplex B-cell fluorospot assay in
which the chromogenic reaction was replaced by a fluo-
rescent detection system for the simultaneous enumera-
tion of total and Env-specific IgG and IgM antibody-
secreting cells (ASCs).
Methods
Anti-Human IgG and IgM antibodies were conjugated
with quantum dot nanocrystals and isotype-specific ASCs
were identified by spots visible at different wavelengths.
ASC counts from single-color ELISpot and fluorospot
assays were compared using serial dilutions of IgG- and
IgM-secreting HIV-1 gp41-specific human hybridoma
cells (5000 to 100 cells/well). In multiplex experiments,
IgG and IgM ASCs were detected using different cell ratios
(1:0, 1:0.5 and 1:1). Gp41-specific responses were evalu-
ated using the cognate gp41 antigen as capture reagent.
Results
Both assays detected equivalent numbers of ASCs at each
cell concentration (r = 0.999, for IgG ASCs and r = 0.998
for IgM ASCs; p < 0.0001) within their linear range. Iso-
type-mismatched nanocrystal-conjugated antibodies did
not interfere with spot development when only one cell
line was used. In multiplex experiments, the percentage of
observed spots was within 3.0% and 2.4% of the expected
spot counts for IgG and IgM, respectively, both of which
were well less than one standard deviation from the
expected value. No statistically significant differences in
the counts of gp41-specific vs total IgG (313 ± 13 vs 335 ±
4 ASCs; p = 0.55. Mean ± SD) and IgM (174 ± 9.9 vs 160
± 21.2 ASCs; p = 0.49) were found.
Conclusion
The fluorospot assay allows simultaneous detection of
anti-HIV-1 Env-specific IgG and IgM ASCs in a multiplex
format. This feature is critical when specimen availability
is limited and multiplexing can be expanded to include
additional specificities.
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